稳定主要分子学反应慢性髓性白血病患者酪氨酸激酶抑制剂减量的研究(DESTINY):非随机2期试验中期分析
该非随机2期试验中期分析在20家英国医院纳入174例慢性髓性白血病患者,评估酪氨酸激酶抑制剂减半剂量治疗12个月的效果。结果显示,MR4队列分子学复发率(2%)显著低于MMR队列(19%),所有复发患者恢复全剂量后均重获MMR,减量期间早期不良反应改善。
要点
- TKI减半剂量治疗12个月,总体分子学复发率为7%,复发者恢复全剂量后均重获MMR。
- MR4队列复发率2%显著低于MMR队列19%,风险比0.12。
- 减量后前3个月不良反应改善,但之后未进一步改善。
核心结论
- TKI减量对大多数对TKI治疗反应良好的患者是安全的,并与症状改善相关。
- 较低的TKI剂量可能维持这些患者的反应,提示此类患者可能被过度治疗。
- 需要进行更大幅度减量的研究。
研究设计与样本
- 非随机2期试验中期分析,在英国20家医院进行。
- 纳入年龄≥18岁、首次慢性期慢性髓性白血病、接受TKI治疗≥3年且稳定MR4(BCR-ABL1:ABL1比值<0·01%)或稳定MMR(BCR-ABL1:ABL1比值持续<0·1%)但不满足MR4至少12个月的患者。
- 患者接受标准TKI剂量的一半(伊马替尼200mg每日、达沙替尼50mg每日或尼洛替尼200mg每日两次)治疗12个月。
- 分子学复发定义为连续两次样本失去MMR(BCR-ABL1:ABL1比值>0·1%)。
- 主要终点为减量后失去MMR并恢复TKI后重获MMR的患者比例,按意向治疗分析。
主要发现
- 2013年12月16日至2015年4月10日共入组174例患者,MMR队列49例,MR4队列125例。
- 12个月半剂量治疗期间,12例(7%)患者出现分子学复发,所有患者在全剂量TKI恢复后4个月内重获MMR(中位恢复时间77天)。
- MR4队列可评估121例中复发3例(2%;90%CI 0·2-4·8),MMR队列可评估48例中复发9例(19%;90%CI 9·5-28·0),MR4队列较MMR队列复发显著降低(风险比0·12,90%CI 0·04-0·37;p=0·0007)。
- 复发与既往TKI种类或TKI治疗持续时间无关。
- 减量后前3个月不良反应(如乏力、腹泻、皮疹、恶心)改善,但之后未进一步改善;报告16例严重不良事件,包括1例死亡,死于既存外周动脉闭塞性疾病加重,该患者仅接受过伊马替尼。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Discontinuation of tyrosine kinase inhibitor (TKI) therapy is feasible for some patients with chronic myeloid leukaemia with deep molecular responses; however, patients with stable major molecular response (MMR), but not MR4, have not been studied, nor has the effect of treatment de-escalation rather than outright cessation. We aimed to examine the effects of treatment de-escalation as a prelude to complete cessation, not only in patients with MR4 or greater, but also in those with MMR but not MR4. METHODS: We did this interim analysis of a non-randomised, phase 2 trial at 20 hospitals in the UK. We recruited patients (aged ≥18 years) with chronic myeloid leukaemia in first chronic phase who had received TKI for 3 years or more and were either in stable MR4 (BCR-ABL1:ABL1 ratio <0·01%; MR4 cohort) or in stable MMR (BCR-ABL1:ABL1 ratio consistently <0·1%) but not MR4 (MMR cohort) for 12 months or longer. Participants received half their standard TKI dose (imatinib 200 mg daily, dasatinib 50 mg daily, or nilotinib 200 mg twice daily) for 12 months. Molecular recurrence was defined as loss of MMR (BCR-ABL1:ABL1 ratio >0·1%) on two consecutive samples. The primary endpoint of this interim analysis was the proportion of patients who lost MMR on de-escalation and regained MMR on TKI resumption. Analyses were by intention to treat. This study is registered with ClinicalTrials.gov, number NCT01804985. FINDINGS: Between Dec 16, 2013 and April 10, 2015, we enrolled 174 patients into the MMR cohort (n=49) or the MR4 cohort (n=125). During the 12 months of half-dose therapy, 12 patients (7%) had molecular recurrence, all of whom regained MMR within 4 months of full-dose TKI resumption (median time to recovery 77 days). Recurrence was significantly lower in the MR4 cohort (three [2%; 90% CI 0·2-4·8] of 121 evaluable patients) than in the MMR cohort (nine [19%; 90% CI 9·5-28·0] of 48 evaluable patients; hazard ratio 0·12, 90% CI 0·04-0·37; p=0·0007), but was unrelated to previous TKI or TKI therapy duration. Adverse events (eg, lethargy, diarrhoea, rash, and nausea) improved during the first 3 months of de-escalation, though not thereafter. 16 serious adverse events were reported, including one fatality due to worsening pre-existing peripheral arterial occlusive disease in a patient who had received only imatinib. INTERPRETATION: TKI de-escalation is safe for most patients with excellent responses to TKI therapy, and is associated with improvement in symptoms. These findings show that lower TKI doses might maintain responses in these patients, implying that such patients could be unnecessarily overtreated. Studies of more ambitious de-escalation are warranted. FUNDING: Newcastle University and Bloodwise.
引用
- Clark RE, Polydoros F, Apperley JF, et al. De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Lancet Haematol. 2017. PMID: 28566209. doi:10.1016/S2352-3026(17)30066-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。